Physician profile
Hersimren Minhas
NPI 1306466701
$1,835.87
in general payments reported to CMS, 2019-2025
17 companies · $730 in 2025
The $730 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $120 · 2023: $313 · 2024: $564 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.71 |
| Education | $398.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $467.83 | 2024-2025 | Ensite, Cardiomems, Jot Dx |
| Kestra Medical Technology Services, INC. | $324.35 | 2025 | Assure Wcd |
| Medtronic, INC. | $270.51 | 2023-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $155.12 | 2024 | Watchman Flx |
| Viiv Healthcare Company | $119.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $76.51 | 2024 | Xarelto |
| Pfizer INC. | $56.46 | 2024-2025 | |
| Terumo Medical Corporation | $40.87 | 2023-2024 | Angio-Seal, Glidesheath Slender, Tr Band |
| Kiniksa Pharmaceuticals International, Plc | $35.72 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $34.35 | 2023 | Farxiga |
| Philips North America LLC | $32.05 | 2024 | (5044) Mcot, (Ck4) Mcot |
| Lantheus Medical Imaging, INC. | $28.08 | 2025 | |
| Alnylam Pharmaceuticals INC. | $23.71 | 2023 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $23.32 | 2024 | Inpefa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.92 | 2025 | |
| Novo Nordisk INC | $14.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hersimren Minhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.